Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

Delayed Quote. Delayed  - 09/23 10:00:00 pm
4.72 USD   -1.87%
09/24 INSIDE THE FDA : Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and it..
09/23 Investigation of Spectrum Pharmaceuticals, Inc. Announced by Law ..
09/22 BRONSTEIN, GEWI : November 21, 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2013 | 03:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) investors of the May 13, 2013, lead plaintiff deadline in a pending lawsuit filed on their behalf. Investors who suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing SPPI@hbsslaw.com.

The lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Investors who wish to move to be a lead plaintiff in the case may also contact the firm by calling (510) 725-3000 and must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
Mark@firmani.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
09/24 INSIDE THE FDA : Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and its Bladder Ca..
09/23 Investigation of Spectrum Pharmaceuticals, Inc. Announced by Law Offices of H..
09/22 BRONSTEIN, GEWIRTZ & GROSSMAN, LLC N : November 21, 2016
09/21 SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Loss..
09/21 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Spectrum Phar..
09/21 Rosen Law Firm Files Securities Class Action Against Spectrum Pharmaceuticals..
09/21 HYNES KELLER & HERNANDEZ, LLC : Announces Investigation of Spectrum Pharmaceutic..
09/20 Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involvin..
09/20 Goldberg Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc.
09/20 SPECTRUM PHARMACEUTICALS NOTIFICATIO : Faruqi & Faruqi, LLP Encourages Investors..
More news
Sector news : Biotechnology & Medical Research - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/19 Disappointment Is Coming For Spectrum Pharmaceuticals
09/14 Ad Comm thumbs down on Spectrum's apaziquone; shares off 4%
09/14 Ad Comm review today for Spectrum Pharma's apaziquone
08/16 Seattle Genetics Has Upcoming Catalysts After All
08/10 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Financials ($)
Sales 2016 136 M
EBIT 2016 -70,1 M
Net income 2016 -79,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 2,79x
Capi. / Sales 2017 3,32x
Capitalization 379 M
More Financials
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,00 $
Spread / Average Target 91%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Anthony E. Maida Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICA..-21.72%379
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results